Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | UBA1 | P22314 | 2/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532722 | 1.00 | MAPT (0.33) | MAPTGAAKDM4EMEN1ALDH1A1 | |
| SCHEMBL5388942 | 0.88 | KDM4E (0.36) | MAPTGAAKDM4EMEN1ALDH1A1 | |
| SCHEMBL533193 | 0.85 | MAPT (0.44) | MAPTGAAKDM4EMEN1ALDH1A1 | |
| SCHEMBL532457 | 0.74 | BRD4 (0.37) | MAPTGAAALDH1A1HPGD | |
| SCHEMBL3641489 | 0.70 | PARP1 (0.30) | — | |
| SCHEMBL533321 | 0.70 | KDM4E (0.45) | MAPTGAAKDM4EMEN1ALDH1A1 | |
| SCHEMBL3419819 | 0.69 | FABP5 (0.39) | MAPTGAAKMT2ATSHR | |
| SCHEMBL7132853 | 0.63 | MAPT (0.53) | MAPTGAAKDM4EMEN1ALDH1A1 | |
| SCHEMBL3419671 | 0.61 | GAA (0.41) | MAPTGAAKDM4EALDH1A1HPGD | |
| SCHEMBL9408601 | 0.58 | MAPT (0.46) | MAPTGAAKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297495-B2 | Hybridization-triggered fluorescent detection of nucleic acids | EPOCH BIOSCIENCES, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070166723-A1 | Hybridization-triggered fluorescent detection of nucleic acids | EPOCH BIOSCIENCES INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-6951930-B2 | Hybridization-triggered fluorescent detection of nucleic acids | EPOCH BIOSCIENCES, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030113765-A1 | Hybridization-triggered fluorescent detection of nucleic acids | EPOCH BIOSCIENCES, INC. (US) | 2003-06-19 | — | — | US | disclosed |
| US-6472153-B1 | COVALENTLY BOUND OLIGONUCLEOTIDE/MINOR GROOVE BINDER/LATENT FLUOROPHORE COMBINATION | EPOCH BIOSCIENCES, INC. | 2002-10-29 | — | — | US | disclosed |
| EP-1224332-A1 | HYBRIDIZATION-TRIGGERED FLUORESCENT DETECTION OF NUCLEIC ACIDS | Epoch Biosciences, Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001031063-A1 | HYBRIDIZATION-TRIGGERED FLUORESCENT DETECTION OF NUCLEIC ACIDS | EPOCH BIOSCIENCES, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070166723-A1 | Hybridization-triggered fluorescent detection of nucleic acids | DDX21, RNGTT, NOP2 | MAPT 3568/4885GAA 1602/4885KDM4E 4882/4885 |
| US-20030113765-A1 | Hybridization-triggered fluorescent detection of nucleic acids | DDX21, RNGTT, NOP2 | MAPT 3568/4885GAA 1602/4885KDM4E 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.